Biologic and anti-obesity drug combo for psoriatic arthritis
Treatments studied
Part of Bones, joints & muscles, Hormones & metabolism, Skin clinical trials.
This study tests whether adding a weight-loss medication (tirzepatide) to a biologic (ixekizumab) helps people with psoriatic arthritis and overweight or obesity. You will need to have biopsies of joint tissue and fat to see how the treatment affects inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old and have been diagnosed with psoriatic arthritis (PsA) for at least 6 months.
- You currently have at least 3 swollen and 3 tender joints (including dactylitis – a swollen whole finger or toe).
- Your body mass index (BMI) is 27 or higher.
- You have not previously taken tirzepatide (Mounjaro) or any other GLP-1 medication, or ixekizumab (Taltz).
- You are willing to have small tissue samples taken (biopsies) from a joint, fat, and possibly skin under local anesthetic, at least twice.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if adding a GLP-1 medication (a type of drug that helps with weight and blood sugar) to your usual psoriatic arthritis treatment can improve your joint and skin symptoms. It is for people with psoriatic arthritis who have not yet achieved good control of their disease and have a higher body weight.
This study tests whether combining a weight-loss medication called tirzepatide (also known as Mounjaro) with a supervised exercise program helps people lose weight and improve their overall health. You'll be in the study for about four months, and you'll get support and monitoring.
This trial tests if semaglutide, a diabetes and weight-loss medication, can improve psoriasis symptoms and reduce inflammation. It may be an option for people with both psoriasis and overweight or obesity, with or without diabetes.
This trial compares two ways to manage weight: taking a GLP-1 medication (like tirzepatide or semaglutide) versus making lifestyle changes without medication. It will help researchers learn which approach works best for people with overweight or obesity.
This trial tests whether adding tirzepatide (a weight-loss and diabetes drug) to ixekizumab (a psoriasis treatment) helps people with moderate-to-severe psoriasis who are overweight or have obesity. It is for those already taking ixekizumab for about 3 months.
This trial tests two study drugs, mirikizumab and tirzepatide, in people with moderate to severe Crohn's disease who also have overweight or obesity. The goal is to see if these treatments can help control Crohn's symptoms and inflammation.
Hear when a new Psoriatic Arthritis (PsA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.